Evidence map›Paper›PMID 27829858›Full record

ArticleCanadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC2016

Pay-for-performance remuneration for pharmacist prescribers' management of hypertension: A substudy of the RxACTION trial.

Sherilyn K D Houle, Theresa L Charrois, Finlay A McAlister, Michael R Kolber, Meagen M Rosenthal, Richard Lewanczuk, Norman R C Campbell, Ross T Tsuyuki

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pharmacist services for non-hospitalised patients.The Cochrane database of systematic reviews · 2018
    Pooled it
  3. Article
  4. Article
  5. Article
  6. A scoping review of research on the prescribing practice of Canadian pharmacists.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC · 2015
    Article
  7. Major concerns remain around pay-for-performance programs in Canada.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Sherilyn K D HouleSchool of Pharmacy (Houle, Tsuyuki), University of Waterloo, Kitchener, Ontario; the Faculty of Pharmacy and Pharmaceutical Sciences (Charrois), the EPICORE Centre/COMPRIS (Charrois, McAlister, Kolber, Tsuyuki), the Department of Medicine (McAlister, Lewanczuk, Tsuyuki) and the Department of Family Medicine (Kolber), University of Alberta, Edmonton; the Cumming School of Medicine (Campbell), University of Calgary, Calgary, Alberta; and the School of Pharmacy (Rosenthal), University of Mississippi, Oxford, Mississippi, USA.
Theresa L CharroisSchool of Pharmacy (Houle, Tsuyuki), University of Waterloo, Kitchener, Ontario; the Faculty of Pharmacy and Pharmaceutical Sciences (Charrois), the EPICORE Centre/COMPRIS (Charrois, McAlister, Kolber, Tsuyuki), the Department of Medicine (McAlister, Lewanczuk, Tsuyuki) and the Department of Family Medicine (Kolber), University of Alberta, Edmonton; the Cumming School of Medicine (Campbell), University of Calgary, Calgary, Alberta; and the School of Pharmacy (Rosenthal), University of Mississippi, Oxford, Mississippi, USA.
Finlay A McAlisterSchool of Pharmacy (Houle, Tsuyuki), University of Waterloo, Kitchener, Ontario; the Faculty of Pharmacy and Pharmaceutical Sciences (Charrois), the EPICORE Centre/COMPRIS (Charrois, McAlister, Kolber, Tsuyuki), the Department of Medicine (McAlister, Lewanczuk, Tsuyuki) and the Department of Family Medicine (Kolber), University of Alberta, Edmonton; the Cumming School of Medicine (Campbell), University of Calgary, Calgary, Alberta; and the School of Pharmacy (Rosenthal), University of Mississippi, Oxford, Mississippi, USA.
Michael R KolberSchool of Pharmacy (Houle, Tsuyuki), University of Waterloo, Kitchener, Ontario; the Faculty of Pharmacy and Pharmaceutical Sciences (Charrois), the EPICORE Centre/COMPRIS (Charrois, McAlister, Kolber, Tsuyuki), the Department of Medicine (McAlister, Lewanczuk, Tsuyuki) and the Department of Family Medicine (Kolber), University of Alberta, Edmonton; the Cumming School of Medicine (Campbell), University of Calgary, Calgary, Alberta; and the School of Pharmacy (Rosenthal), University of Mississippi, Oxford, Mississippi, USA.
Meagen M RosenthalSchool of Pharmacy (Houle, Tsuyuki), University of Waterloo, Kitchener, Ontario; the Faculty of Pharmacy and Pharmaceutical Sciences (Charrois), the EPICORE Centre/COMPRIS (Charrois, McAlister, Kolber, Tsuyuki), the Department of Medicine (McAlister, Lewanczuk, Tsuyuki) and the Department of Family Medicine (Kolber), University of Alberta, Edmonton; the Cumming School of Medicine (Campbell), University of Calgary, Calgary, Alberta; and the School of Pharmacy (Rosenthal), University of Mississippi, Oxford, Mississippi, USA.
Richard LewanczukSchool of Pharmacy (Houle, Tsuyuki), University of Waterloo, Kitchener, Ontario; the Faculty of Pharmacy and Pharmaceutical Sciences (Charrois), the EPICORE Centre/COMPRIS (Charrois, McAlister, Kolber, Tsuyuki), the Department of Medicine (McAlister, Lewanczuk, Tsuyuki) and the Department of Family Medicine (Kolber), University of Alberta, Edmonton; the Cumming School of Medicine (Campbell), University of Calgary, Calgary, Alberta; and the School of Pharmacy (Rosenthal), University of Mississippi, Oxford, Mississippi, USA.
Norman R C CampbellSchool of Pharmacy (Houle, Tsuyuki), University of Waterloo, Kitchener, Ontario; the Faculty of Pharmacy and Pharmaceutical Sciences (Charrois), the EPICORE Centre/COMPRIS (Charrois, McAlister, Kolber, Tsuyuki), the Department of Medicine (McAlister, Lewanczuk, Tsuyuki) and the Department of Family Medicine (Kolber), University of Alberta, Edmonton; the Cumming School of Medicine (Campbell), University of Calgary, Calgary, Alberta; and the School of Pharmacy (Rosenthal), University of Mississippi, Oxford, Mississippi, USA.
Ross T TsuyukiSchool of Pharmacy (Houle, Tsuyuki), University of Waterloo, Kitchener, Ontario; the Faculty of Pharmacy and Pharmaceutical Sciences (Charrois), the EPICORE Centre/COMPRIS (Charrois, McAlister, Kolber, Tsuyuki), the Department of Medicine (McAlister, Lewanczuk, Tsuyuki) and the Department of Family Medicine (Kolber), University of Alberta, Edmonton; the Cumming School of Medicine (Campbell), University of Calgary, Calgary, Alberta; and the School of Pharmacy (Rosenthal), University of Mississippi, Oxford, Mississippi, USA.
Campbell University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo be sustainable, pharmacists providing direct patient care must receive appropriate payment for these services. This prespecified substudy of the RxACTION trial (a randomized trial of pharmacist prescribing vs usual care in patients with above-target blood pressure [BP]) aimed to determine if BP reduction achieved differed between patients whose pharmacist was paid by pay-for-performance (P4P) vs fee-for-service (FFS).

methodsWithin RxACTION, patients with elevated BP assigned to the pharmacist prescribing group were further randomized to P4P or FFS payment for the pharmacist. In FFS, pharmacists received $150 for the initial visit and $75 for follow-up visits. P4P included FFS payments plus incentives of $125 and $250 for each patient who reached 50% and 100% of the BP target, respectively. The primary outcome was difference in change in systolic BP between P4P and FFS groups.

resultsA total of 89 patients were randomized to P4P and 92 to the FFS group. Patients' average (SD) age was 63.0 (13.2) years, 49% were male and 76% were on antihypertensive drug therapy at baseline, taking a median of 2 (interquartile range = 1) medications. Mean systolic BP reductions in the P4P and FFS groups were 19.7 (SD = 18.4) vs 17.0 (SD = 16.4) mmHg, respectively (

conclusionsThis trial of pharmacist prescribing found substantial reductions in systolic BP among poorly controlled hypertensive individuals but with no appreciable difference when pharmacists were paid by P4P vs FFS.

Identifiers

PMID27829858
PMCPMC5089333
OpenAlexW2528382773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.